189 related articles for article (PubMed ID: 27903457)
1. Glass-forming ability of compounds in marketed amorphous drug products.
Wyttenbach N; Kuentz M
Eur J Pharm Biopharm; 2017 Mar; 112():204-208. PubMed ID: 27903457
[TBL] [Abstract][Full Text] [Related]
2. Theoretical Considerations of the Prigogine-Defay Ratio with Regard to the Glass-Forming Ability of Drugs from Undercooled Melts.
Wyttenbach N; Kirchmeyer W; Alsenz J; Kuentz M
Mol Pharm; 2016 Jan; 13(1):241-50. PubMed ID: 26587865
[TBL] [Abstract][Full Text] [Related]
3. Understanding the glass-forming ability of active pharmaceutical ingredients for designing supersaturating dosage forms.
Kawakami K; Usui T; Hattori M
J Pharm Sci; 2012 Sep; 101(9):3239-48. PubMed ID: 22531946
[TBL] [Abstract][Full Text] [Related]
4. Early drug development predictions of glass-forming ability and physical stability of drugs.
Mahlin D; Bergström CA
Eur J Pharm Sci; 2013 May; 49(2):323-32. PubMed ID: 23557841
[TBL] [Abstract][Full Text] [Related]
5. Computational predictions of glass-forming ability and crystallization tendency of drug molecules.
Alhalaweh A; Alzghoul A; Kaialy W; Mahlin D; Bergström CA
Mol Pharm; 2014 Sep; 11(9):3123-32. PubMed ID: 25014125
[TBL] [Abstract][Full Text] [Related]
6. Physical stability of drugs after storage above and below the glass transition temperature: Relationship to glass-forming ability.
Alhalaweh A; Alzghoul A; Mahlin D; Bergström CAS
Int J Pharm; 2015 Nov; 495(1):312-317. PubMed ID: 26341321
[TBL] [Abstract][Full Text] [Related]
7. Influence of Glass Forming Ability on the Physical Stability of Supersaturated Amorphous Solid Dispersions.
Blaabjerg LI; Bulduk B; Lindenberg E; Löbmann K; Rades T; Grohganz H
J Pharm Sci; 2019 Aug; 108(8):2561-2569. PubMed ID: 30878513
[TBL] [Abstract][Full Text] [Related]
8. Crystallization tendency of APIs possessing different thermal and glass related properties in amorphous solid dispersions.
Kapourani A; Vardaka E; Katopodis K; Kachrimanis K; Barmpalexis P
Int J Pharm; 2020 Apr; 579():119149. PubMed ID: 32070762
[TBL] [Abstract][Full Text] [Related]
9. An investigation into the crystallization tendency/kinetics of amorphous active pharmaceutical ingredients: A case study with dipyridamole and cinnarizine.
Baghel S; Cathcart H; Redington W; O'Reilly NJ
Eur J Pharm Biopharm; 2016 Jul; 104():59-71. PubMed ID: 27108783
[TBL] [Abstract][Full Text] [Related]
10. Is there a correlation between the glass forming ability of a drug and its supersaturation propensity?
Blaabjerg LI; Lindenberg E; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2018 Mar; 538(1-2):243-249. PubMed ID: 29341914
[TBL] [Abstract][Full Text] [Related]
11. Toward in silico prediction of glass-forming ability from molecular structure alone: a screening tool in early drug development.
Mahlin D; Ponnambalam S; Höckerfelt MH; Bergström CA
Mol Pharm; 2011 Apr; 8(2):498-506. PubMed ID: 21344945
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters.
Nurzyńska K; Booth J; Roberts CJ; McCabe J; Dryden I; Fischer PM
Mol Pharm; 2015 Sep; 12(9):3389-98. PubMed ID: 26236939
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Physical (In)Stability of Spray-Dried Amorphous Drugs: Relationship with Glass-Forming Ability and Physicochemical Properties.
Edueng K; Bergström CAS; Gråsjö J; Mahlin D
Pharmaceutics; 2019 Aug; 11(9):. PubMed ID: 31438566
[TBL] [Abstract][Full Text] [Related]
14. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
15. Thermodynamic behavior of glassy state of structurally related compounds.
Kaushal AM; Bansal AK
Eur J Pharm Biopharm; 2008 Aug; 69(3):1067-76. PubMed ID: 18420396
[TBL] [Abstract][Full Text] [Related]
16. Influence of preparation pathway on the glass forming ability.
Blaabjerg LI; Lindenberg E; Rades T; Grohganz H; Löbmann K
Int J Pharm; 2017 Apr; 521(1-2):232-238. PubMed ID: 28232267
[TBL] [Abstract][Full Text] [Related]
17. Glass Forming Ability of Amorphous Drugs Investigated by Continuous Cooling and Isothermal Transformation.
Blaabjerg LI; Lindenberg E; Löbmann K; Grohganz H; Rades T
Mol Pharm; 2016 Sep; 13(9):3318-25. PubMed ID: 27529364
[TBL] [Abstract][Full Text] [Related]
18. [Amorphous form in pharmaceutical technological research].
Mártha C; Jójártné LO; Szabóné RP
Acta Pharm Hung; 2011; 81(1):37-42. PubMed ID: 21595304
[TBL] [Abstract][Full Text] [Related]
19. Myth or Truth: The Glass Forming Ability Class III Drugs Will Always Form Single-Phase Homogenous Amorphous Solid Dispersion Formulations.
Panini P; Rampazzo M; Singh A; Vanhoutte F; Van den Mooter G
Pharmaceutics; 2019 Oct; 11(10):. PubMed ID: 31614985
[TBL] [Abstract][Full Text] [Related]
20. Impact of Intermolecular Interactions, Dimeric Structures on the Glass Forming Ability of Naproxen, and a Series of Its Derivatives.
Minecka A; Kaminska E; Tarnacka M; Grudzka-Flak I; Bartoszek M; Wolnica K; Dulski M; Kaminski K; Paluch M
Mol Pharm; 2018 Oct; 15(10):4764-4776. PubMed ID: 30156420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
